Female injecting drug users: human immunodeficiency virus risk behavior and intervention needs. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Female injecting drug users: human immunodeficiency virus risk behavior and intervention needs.

J Prof Nurs. 1998 Nov-Dec;14(6):361-9. Unique Identifier : AIDSLINE MED/99056139
Brown EJ; Center for Urban Health Research, School of Nursing, University; of Pennsylvania, Philadelphia 19104, USA.

Abstract: Injecting drug use and heterosexual contact are the major exposure categories for women acquiring human immunodeficiency virus (HIV). The purpose of this study was to explore the relationship of acquired immunodeficiency syndrome (AIDS) risk perception, perceived seriousness of HIV, drug use self-efficacy, sexual self-efficacy, and social support for HIV/AIDS risk behavior among female injecting drug users (IDUs). A random sample of 140 female IDUs was interviewed using a structured questionnaire. The data were analyzed by descriptive statistics and logistic regression. Self-efficacy for preventive sexual behavior and social support were predictive of condom use with primary partners P = .01 and P = .001, respectively. Self-efficacy for preventive drug use was predictive of risky injection behavior (P = .004) and risky injection location (P = .003). The results suggest that HIV prevention programs targeting female IDUs should include strategies that incorporate their support networks and strengthen preventive self-efficacy. Brief intervention strategies that nurses can carry out with female IDUs are suggested.
Keywords: JOURNAL ARTICLE Adult Female Human HIV Infections/*PREVENTION & CONTROL/TRANSMISSION Logistic Models Middle Age New York City Pilot Projects *Self Efficacy Sex Behavior Social Support Substance Abuse, Intravenous/*COMPLICATIONS/PSYCHOLOGY Support, Non-U.S. Gov'tKWDjournalarticleadultfemalehumanhivinfections/KWDprevention&control/transmissionlogisticmodelsmiddleagenewyorkcitypilotprojectsKWDselfefficacysexbehaviorsocialsupportsubstanceabuse,intravenous/KWDcomplications/psychologysupport,non-uKWDsKWDgov't
990330
A9931057

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .